Literature DB >> 18757529

Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid.

Jonathan M Maher1, Lauren M Aleksunes, Matthew Z Dieter, Yuji Tanaka, Jeffrey M Peters, Jose E Manautou, Curtis D Klaassen.   

Abstract

Perfluorooctanoic acid and perfluorodecanoic acid (PFDA) are commonly used as emulsifiers and surfactants in fluoropolymer manufacturing and are known peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists. PPAR alpha activation induces beta- and omega-oxidation enzymes such as Cyp4a14 and acyl-CoA oxidase, which are a likely cause of subsequent oxidative stress and peroxisome proliferation. Conversely, NF-E2-related factor-2 (Nrf2) is a transcription factor that protects against oxidative stress and inflammation by regulating several detoxification and xenobiotic transporter genes. Because PFDA markedly induces hepatic metabolism and oxidative stress, we hypothesized that PFDA exposure would increase expression of hepatic efflux multidrug resistance-associated protein (Mrp) transporters. A single PFDA dose (80 mg/kg) administered to mice increased hepatic Mrp3 (fourfold) and Mrp4 (31-fold) mRNA expression. Upregulation of Mrp3 and Mrp4 correlated with elevated serum-conjugated bilirubin and bile acids, respectively. To determine the mechanism of Mrp3 and Mrp4 induction, PFDA was administered to Nrf2-null mice, PPAR alpha-null mice, and mice pretreated with gadolinium chloride, a Kupffer cell-depleting chemical capable of inhibiting the inflammatory cytokine response. In both PPAR alpha- and Nrf2-null mice, maximal induction of Mrp3 and Mrp4 mRNA after PFDA administration was attenuated. Gadolinium chloride pretreatment reduced serum and hepatic tumor necrosis factor-alpha levels after PFDA treatment, as well as Mrp4 mRNA expression by 30%, suggesting that Kupffer cell-derived mediators may contribute to Mrp induction. Thus, after PFDA administration, the liver mounts a compensatory hepatoprotective response via PPAR alpha and Nrf2, markedly increasing Mrp3 and Mrp4 expression, with corresponding increases in serum of known Mrp3 and Mrp4 substrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757529      PMCID: PMC2721675          DOI: 10.1093/toxsci/kfn177

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  59 in total

Review 1.  Regulation of gamma-glutamylcysteine synthetase subunit gene expression: insights into transcriptional control of antioxidant defenses.

Authors:  A C Wild; R T Mulcahy
Journal:  Free Radic Res       Date:  2000-04

2.  Characterization of multidrug resistance-associated protein 2 in the hepatocellular disposition of 4-hydroxynonenal.

Authors:  John F Reichard; Jonathan A Doorn; Franz Simon; Melinda S Taylor; Dennis R Petersen
Journal:  Arch Biochem Biophys       Date:  2003-03-15       Impact factor: 4.013

3.  Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver.

Authors:  M G Donner; D Keppler
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

Review 4.  Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis.

Authors:  A V Yeldandi; M S Rao; J K Reddy
Journal:  Mutat Res       Date:  2000-03-17       Impact factor: 2.433

5.  Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal.

Authors:  J Renes; E E de Vries; G J Hooiveld; I Krikken; P L Jansen; M Müller
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

Review 6.  Regulation of genes encoding NAD(P)H:quinone oxidoreductases.

Authors:  A K Jaiswal
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

Review 7.  The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis.

Authors:  Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2002-07-31       Impact factor: 4.102

8.  Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis.

Authors:  Gernot Zollner; Peter Fickert; Dagmar Silbert; Andrea Fuchsbichler; Hanns Ulrich Marschall; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

9.  Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).

Authors:  Noam Zelcer; Glen Reid; Peter Wielinga; Annemieke Kuil; Ingrid van der Heijden; John D Schuetz; Piet Borst
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

10.  Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2.

Authors:  Lauren M Aleksunes; Angela L Slitt; Jonathan M Maher; Lisa M Augustine; Michael J Goedken; Jefferson Y Chan; Nathan J Cherrington; Curtis D Klaassen; José E Manautou
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-31       Impact factor: 4.219

View more
  43 in total

1.  Colloidal carbon stimulation of Kupffer cells triggers Nrf2 activation in the isolated perfused rat liver.

Authors:  Bárbara Núñez; Romina Vargas; Iván Castillo; Luis A Videla
Journal:  J Mol Histol       Date:  2012-03-30       Impact factor: 2.611

2.  Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Authors:  Luis E Gomez-Quiroz; Daekwan Seo; Yun-Han Lee; Mitsuteru Kitade; Timo Gaiser; Matthew Gillen; Seung-Bum Lee; Ma Concepcion Gutierrez-Ruiz; Elizabeth A Conner; Valentina M Factor; Snorri S Thorgeirsson; Jens U Marquardt
Journal:  Toxicology       Date:  2016-07-06       Impact factor: 4.221

3.  Renal efflux transporter expression in pregnant mice with Type I diabetes.

Authors:  Lindsay L Yacovino; Lauren M Aleksunes
Journal:  Toxicol Lett       Date:  2012-04-17       Impact factor: 4.372

Review 4.  Nrf2:INrf2 (Keap1) signaling in oxidative stress.

Authors:  James W Kaspar; Suryakant K Niture; Anil K Jaiswal
Journal:  Free Radic Biol Med       Date:  2009-08-07       Impact factor: 7.376

Review 5.  Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species.

Authors:  Ludwik Gorczyca; Lauren M Aleksunes
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-14       Impact factor: 4.481

Review 6.  Regulation of Nrf2-an update.

Authors:  Suryakant K Niture; Raju Khatri; Anil K Jaiswal
Journal:  Free Radic Biol Med       Date:  2013-02-19       Impact factor: 7.376

Review 7.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

8.  Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.

Authors:  Mark J Canet; Matthew D Merrell; Bryan G Harder; Jonathan M Maher; Tongde Wu; Andrew J Lickteig; Jonathan P Jackson; Donna D Zhang; Masayuki Yamamoto; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-10-27       Impact factor: 3.922

9.  Pregnancy represses induction of efflux transporters in livers of type I diabetic mice.

Authors:  Lauren M Aleksunes; Jialin Xu; Eugenia Lin; Xia Wen; Michael J Goedken; Angela L Slitt
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

Review 10.  Altered Expression of Transporters, its Potential Mechanisms and Influences in the Liver of Rodent Models Associated with Diabetes Mellitus and Obesity.

Authors:  Leilei Ma; Lei He; Le Wang; Li Li; Xuena Lin; Guoyu Pan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-06       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.